Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Developmental Therapeutics—Immunotherapy

Type: Oral Abstract Session

Time: Monday June 5, 1:15 PM to 4:15 PM

Location: Hall D1

Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.

Sub-category:
Immune Checkpoint Inhibitors

Category:
Developmental Therapeutics—Immunotherapy

Meeting:
2017 ASCO Annual Meeting

Abstract No:
3003

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 3003)

Author(s): Raymond P. Perez, Matthew John Riese, Karl D. Lewis, Mansoor N. Saleh, Adil Daud, Jordan Berlin, James J. Lee, Sutapa Mukhopadhyay, Li Zhou, Gul Serbest, Omid Hamid; University of Kansas Clinical Research Center, Fairway, KS; Medical College of Wisconsin, Milwaukee, WI; University of Colorado, Aurora, CO; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; University of California, San Francisco, San Francisco, CA; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN; University of Pittsburgh School of Medicine, Pittsburgh, PA; Bristol-Myers Squibb, Princeton, NJ; Incyte Corporation, Wilmington, DE; The Angeles Clinic and Research Institute, Los Angeles, CA

Abstract Disclosures

Abstract:

Background: ECHO-204 is an ongoing, open-label, phase 1/2 (P1/2) study of epacadostat (E; potent and selective oral inhibitor of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1) plus PD-1 inhibitor nivolumab (N) in patients (pts) with advanced cancers (NSCLC, MEL, OVC, CRC, SCCHN, B-cell NHL [including DLBCL], GBM). Preliminary P1/2 safety and tolerability outcomes for the overall study population and P2 response for select tumor types (SCCHN, MEL, OVC, CRC) are reported. Methods: In P1 dose escalation, pts received E (25, 50, 100, 300 mg BID) + N (3 mg/kg Q2W); in P2 cohort expansion, pts received E (100 or 300 mg BID) + N (240 mg Q2W). Safety/tolerability was assessed in pts receiving ≥1 E + N dose. Response was assessed in RECIST v1.1 evaluable pts; for recently enrolled pt subgroups, only preliminary DCR (CR+PR+SD) is presented. Results: As of 29OCT2016,241 pts (P1, n = 36; P2, n = 205) were enrolled. No DLT was observed in P1. Most common TRAEs (≥15%) in pts treated with E 100 mg (n = 70) and E 300 mg (n = 135) were rash (33% and 22%, respectively), fatigue (26% and 31%), and nausea (24% and 19%). Rash was the most common grade ≥3 TRAE in E 100 mg and E 300 mg subgroups (10% and 12%). TRAEs led to discontinuation in 7% (E 100 mg) and 13% (E 300 mg) of pts. There were no TR-deaths. For the 23 recently enrolled, efficacy-evaluable SCCHN pts treated with E 300 mg, preliminary DCR was 70% (n = 16). Of 30 MEL pts, 8 were treated with E 100 mg and 22 were more recently enrolled and treated with E 300 mg. ORR (CR+PR) and DCR in MEL pts treated with E 100 mg were 75% (n = 6; all PR) and 100% (n = 8; 2 SD), respectively. Preliminary DCR in MEL pts treated with E 300 mg was 64% (n = 14). Of 29 OVC pts, 18 were treated with E 100 mg and 11 with E 300 mg.ORR and DCR for OVC pts treated with E 100 mg were 11% (n = 2; 2 PR) and 28% (n = 5; 3 SD); for 11 OVC pts treated with E 300 mg, ORR and DCR were 18% (n = 2; 2 PR) and 36% (n = 4; 2 SD).For 25 CRC pts (all E 100 mg), ORR and DCR were 4% (n = 1; PR) and 24% (n = 6; 5 SD).Safety/efficacy evaluations are ongoing for all cohorts. Conclusions: E + N was generally well tolerated up to the maximum E 300-mg dose. P2 ORR/DCR outcomes are promising, particularly in SCCHN and MEL pts. Updated data will be presented at the meeting. Clinical trial information: NCT02327078

 
Other Abstracts in this Sub-Category:

 

1. Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors.

Meeting: 2017 ASCO Annual Meeting Abstract No: 104 First Author: Lillian L. Siu
Category: Developmental Therapeutics—Immunotherapy - Immune Checkpoint Inhibitors

 

2. Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.

Meeting: 2017 ASCO Annual Meeting Abstract No: 3004 First Author: Lawrence Fong
Category: Developmental Therapeutics—Immunotherapy - Immune Checkpoint Inhibitors

 

3. CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors.

Meeting: 2017 ASCO Annual Meeting Abstract No: 3005 First Author: Kyriakos P. Papadopoulos
Category: Developmental Therapeutics—Immunotherapy - Immune Checkpoint Inhibitors

 

More...